Payment overview · 2025
General Payments
$646.49
37 reported records · 13 companies
Healthcare provider profile · identity verified
Christopher Collins Lee, MD
Allopathic & Osteopathic Physicians|Family Medicine · BATON ROUGE, LA · NPI 1356334866
Verified facts
What the public records show
CMS Open Payments records show Christopher Collins Lee, MD received $646.49 in general payments during 2025 across 37 reported records.
Novo Nordisk Inc accounted for 23.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 184 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 184 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 158 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $148.62 | 23.0% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $137.10 | 21.2% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $51.23 | 7.9% | 3 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $49.47 | 7.7% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $44.72 | 6.9% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.69 | 6.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $40.58 | 6.3% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.16 | 5.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.77 | 5.1% | 2 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $18.16 | 2.8% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $17.64 | 2.7% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $16.37 | 2.5% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $13.98 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $646.49 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $84.35 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $80.85 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $76.60 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $64.27 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $64.27 | 4 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $56.25 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $51.23 | 3 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $49.47 | 3 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $49.47 | 3 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $49.47 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $44.72 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $44.72 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $35.16 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $24.30 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $24.30 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $17.64 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.04 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.04 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.28 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.28 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.67 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $13.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 58 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 184 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 159 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 158 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 35 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
184 | 41 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
35 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
184 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
159 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
158 | 33 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
58 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
22 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 779 | 212 |
| Levothyroxine Sodium | Levothyroxine Sodium | 766 | 190 |
| Atorvastatin Calcium | Atorvastatin Calcium | 599 | 169 |
| Metformin Hcl | Metformin Hcl | 500 | 133 |
| Pantoprazole Sodium | Pantoprazole Sodium | 294 | 83 |
| Hydrochlorothiazide | Hydrochlorothiazide | 291 | 76 |
| Gabapentin | Gabapentin | 290 | 68 |
| Lisinopril | Lisinopril | 263 | 68 |
| Sertraline Hcl | Sertraline Hcl | 254 | 59 |
| Simvastatin | Simvastatin | 232 | 59 |
| Losartan Potassium | Losartan Potassium | 221 | 60 |
| Omeprazole | Omeprazole | 204 | 52 |
| Montelukast Sodium | Montelukast Sodium | 202 | 55 |
| Trazodone Hcl | Trazodone Hcl | 192 | 55 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 190 | 58 |
| Jardiance | Empagliflozin | 184 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 182 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 174 | 49 |
| Zolpidem Tartrate | Zolpidem Tartrate | 170 | 24 |
| Allopurinol | Allopurinol | 168 | 39 |
| Mounjaro | Tirzepatide | 159 | 25 |
| Ozempic | Semaglutide | 158 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 148 | 50 |
| Furosemide | Furosemide | 147 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 147 | 40 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 143 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 125 | 49 |
| Glimepiride | Glimepiride | 118 | 30 |
| Nebivolol Hcl | Nebivolol Hcl | 117 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 114 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 108 | 45 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 107 | 89 |
| Synthroid | Levothyroxine Sodium | 102 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 101 | 27 |
| Atenolol | Atenolol | 100 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 99 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 99 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 93 | 75 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 89 | 21 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 84 | 19 |
| Potassium Chloride | Potassium Chloride | 80 | 32 |
| Alprazolam | Alprazolam | 77 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 29 |
| Cephalexin | Cephalexin | 75 | 63 |
| Pioglitazone Hcl | Pioglitazone Hcl | 70 | 19 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 69 | 19 |
| Prednisone | Prednisone | 65 | 55 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 63 | 12 |
| Meloxicam | Meloxicam | 62 | 19 |
| Methylprednisolone | Methylprednisolone | 61 | 58 |
| Eliquis | Apixaban | 58 | 11 |
| Ezetimibe | Ezetimibe | 57 | 16 |
| Tramadol Hcl | Tramadol Hcl | 56 | 18 |
| Lovastatin | Lovastatin | 55 | 15 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 54 | 13 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 54 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 51 | 17 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 49 | 16 |
| Ondansetron Odt | Ondansetron | 49 | 27 |
| Valsartan | Valsartan | 49 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 36 |
| Eszopiclone | Eszopiclone | 48 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 47 | 33 |
| Paroxetine Hcl | Paroxetine Hcl | 47 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | 13 |
| Irbesartan | Irbesartan | 45 | suppressed |
| Azithromycin | Azithromycin | 44 | 42 |
| Metformin Hcl Er | Metformin Hcl | 44 | 13 |
| Fluconazole | Fluconazole | 43 | 27 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 42 | 12 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 41 | 11 |
| Donepezil Hcl | Donepezil Hcl | 41 | 13 |
| Januvia | Sitagliptin Phosphate | 41 | suppressed |
| Lorazepam | Lorazepam | 41 | suppressed |
| Bupropion Xl | Bupropion Hcl | 40 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 40 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Cefdinir | Cefdinir | 38 | 38 |
| Ipratropium Bromide | Ipratropium Bromide | 38 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 37 | suppressed |
| Pregabalin | Pregabalin | 35 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 34 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 33 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 32 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Bumetanide | Bumetanide | 30 | suppressed |
| Carvedilol | Carvedilol | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | 11 |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Celecoxib | Celecoxib | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Mupirocin | Mupirocin | 26 | 23 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 15 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 25 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | 20 |
| Naproxen | Naproxen | 23 | suppressed |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Famotidine | Famotidine | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 16 | suppressed |
| Tadalafil | Tadalafil | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Felodipine Er | Felodipine | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 14 | 12 |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 14 | 14 |
| Topiramate | Topiramate | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Verapamil Sr | Verapamil Hcl | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Qulipta | Atogepant | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $646.49 · 37 records | Novo Nordisk Inc | ABRYSVO, AREXVY, Cologuard Collection Kit, ELIQUIS, Flector, INSPIRE, JARDIANCE, JATENZO, KRYSTEXXA, Licart, MOUNJARO, NURTEC ODT, Natroba, OTEZLA, Ozempic, PREVNAR 20, REPATHA, Rybelsus, SHINGRIX, Spinosad, TRELEGY ELLIPTA, Tirosint, UNITHROID, VOQUEZNA, Wegovy, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error